Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
220.36
-0.14 (-0.06%)
At close: Dec 5, 2025, 4:00 PM EST
219.64
-0.72 (-0.33%)
After-hours: Dec 5, 2025, 7:16 PM EST
Cidara Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | - | 1.28 | 23.28 | 23.5 | 49.57 | 12.07 | Upgrade
|
| Revenue Growth (YoY) | - | -94.52% | -0.91% | -52.60% | 310.81% | -42.30% | Upgrade
|
| Cost of Revenue | 131.82 | 71.88 | 36.76 | 30.17 | 73.09 | 68.02 | Upgrade
|
| Gross Profit | -131.82 | -70.6 | -13.48 | -6.67 | -23.52 | -55.95 | Upgrade
|
| Selling, General & Admin | 28.09 | 20.62 | 13.58 | 15.23 | 18.74 | 15.9 | Upgrade
|
| Operating Expenses | 28.09 | 20.62 | 13.58 | 15.23 | 18.74 | 15.9 | Upgrade
|
| Operating Income | -159.91 | -91.22 | -27.06 | -21.9 | -42.26 | -71.85 | Upgrade
|
| Interest Expense | - | - | - | - | -0.21 | -0.26 | Upgrade
|
| Interest & Investment Income | 10.77 | 5.81 | 2 | 0.19 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.11 | - | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -149.25 | -85.41 | -25.07 | -21.71 | -42.47 | -72.11 | Upgrade
|
| Other Unusual Items | 9.45 | - | - | - | - | - | Upgrade
|
| Pretax Income | -184.8 | -170.29 | -25.07 | -21.71 | -42.47 | -72.11 | Upgrade
|
| Income Tax Expense | - | - | 0.02 | 0.01 | - | - | Upgrade
|
| Earnings From Continuing Operations | -184.8 | -170.29 | -25.08 | -21.72 | -42.47 | -72.11 | Upgrade
|
| Earnings From Discontinued Operations | 0.06 | 0.46 | 2.15 | -11.86 | - | - | Upgrade
|
| Net Income | -184.74 | -169.83 | -22.93 | -33.58 | -42.47 | -72.11 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 2.76 | Upgrade
|
| Net Income to Common | -184.74 | -169.83 | -22.93 | -33.58 | -42.47 | -74.87 | Upgrade
|
| Shares Outstanding (Basic) | 17 | 6 | 4 | 3 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 6 | 4 | 3 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | 229.65% | 45.26% | 25.15% | 33.18% | 26.22% | 38.83% | Upgrade
|
| EPS (Basic) | -11.11 | -26.75 | -5.25 | -9.61 | -16.19 | -36.03 | Upgrade
|
| EPS (Diluted) | -11.11 | -26.75 | -5.25 | -9.61 | -16.20 | -36.03 | Upgrade
|
| Free Cash Flow | -132.94 | -176.66 | -22.94 | -28.59 | -25.27 | -54.6 | Upgrade
|
| Free Cash Flow Per Share | -8.00 | -27.82 | -5.25 | -8.19 | -9.64 | -26.27 | Upgrade
|
| Gross Margin | - | - | -57.90% | -28.40% | -47.44% | - | Upgrade
|
| Operating Margin | - | -7154.43% | -116.22% | -93.20% | -85.24% | -595.42% | Upgrade
|
| Profit Margin | - | -13319.77% | -98.49% | -142.94% | -85.67% | -620.48% | Upgrade
|
| Free Cash Flow Margin | - | -13855.84% | -98.51% | -121.69% | -50.98% | -452.45% | Upgrade
|
| EBITDA | -159.78 | -91.07 | -26.95 | -21.76 | -42.07 | -71.56 | Upgrade
|
| EBITDA Margin | - | - | -115.74% | -92.59% | -84.86% | - | Upgrade
|
| D&A For EBITDA | 0.13 | 0.15 | 0.11 | 0.14 | 0.19 | 0.29 | Upgrade
|
| EBIT | -159.91 | -91.22 | -27.06 | -21.9 | -42.26 | -71.85 | Upgrade
|
| EBIT Margin | - | - | -116.22% | -93.20% | -85.24% | - | Upgrade
|
| Revenue as Reported | - | 1.28 | 23.28 | 23.5 | 49.57 | 12.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.